GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Faes Farma SA (XMAD:FAE) » Definitions » Retained Earnings

Faes Farma (XMAD:FAE) Retained Earnings : €124.2 Mil (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Faes Farma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Faes Farma's retained earnings for the quarter that ended in Jun. 2023 was €124.2 Mil.

Faes Farma's quarterly retained earnings declined from Dec. 2022 (€147.5 Mil) to Mar. 2023 (€0.0 Mil) but then increased from Mar. 2023 (€0.0 Mil) to Jun. 2023 (€124.2 Mil).

Faes Farma's annual retained earnings increased from Dec. 2021 (€127.0 Mil) to Dec. 2022 (€147.5 Mil) and increased from Dec. 2022 (€147.5 Mil) to Dec. 2023 (€165.8 Mil).


Faes Farma Retained Earnings Historical Data

The historical data trend for Faes Farma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faes Farma Retained Earnings Chart

Faes Farma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.63 104.27 127.01 147.48 165.81

Faes Farma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 147.48 - 124.17 165.81

Faes Farma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Faes Farma  (XMAD:FAE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Faes Farma (XMAD:FAE) Business Description

Traded in Other Exchanges
Address
Maximo Aguirre, 14, Leioa, Vizcaya, ESP, 48940
Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Faes Farma (XMAD:FAE) Headlines

No Headlines